MedTrace Logo

Diffusion Basis Spectrum Imaging of the Prostate

NCT04420702 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2025-07-18

No results posted yet for this study

Summary

Diffusion Basis Spectrum Imaging (DBSI) represents a potential leap forward in improving prostate cancer early detection: a non-invasive and accurate imaging test for clinically significant prostate cancer.

Conditions

Interventions

DEVICE

MRI with DBSI analysis

-The procedure will take approximately 1 hour of the participant's time

Sponsors & Collaborators

  • American Cancer Society, Inc.

    collaborator OTHER

  • The Foundation for Barnes-Jewish Hospital

    collaborator OTHER

  • Midwest Stone Institute.

    collaborator OTHER

  • National Cancer Institute (NCI)

    collaborator NIH

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Joseph Ippolito, M.D. · Washington University School of Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-27
Primary Completion
2027-05-31
Completion
2027-05-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04420702 on ClinicalTrials.gov